Contrast-enhanced mammography vs. MRI: Neoadjuvant therapy response in breast cancer

Contrast-enhanced mammography vs. MRI: Neoadjuvant therapy response in breast cancer
A, CC (left) and MLO (right) low-energy images from pre-NAT CEM performed on 25th day of luteal phase show a 60-mm architectural distortion (line on CC) in the central portion of the right breast. B, CC (left) and MLO (right) recombined images from pre-NAT CEM show marked background parenchymal enhancement, hindering lesion evaluation; 90-mm non-mass regional enhancement (line) was described. C, Axial fat-saturated T1-weighted unenhanced MR image shows a 70-mm hypointense irregular mass (line) with not circumscribed margins in the central portion of right breast. D, Axial fat-saturated T1-weighted post-contrast MR images shows corresponding fast initial enhancement (line) with delayed plateau. Credit: American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

According to the ARRS American Journal of Roentgenology (AJR), contrast-enhanced mammography (CEM) may be a useful alternative test for neoadjuvant therapy (NAT) response assessment in patients with breast cancer who are unable to undergo MRI.

"After NAT for , CEM and MRI yielded comparable assessments of lesion size (both slightly overestimated vs pathology) and RECIST categories, and no significant difference in specificity for pathologic complete response," wrote corresponding author Rubina Manuela Trimboli of IRCCS Humanitas Research Hospital in Milan, Italy. Noting that MRI had higher sensitivity for pathologic complete response, Trimboli wrote that "delayed CEM acquisition may help detect residual ductal carcinoma in situ (DCIS)."

Trimboli and the team's prospective study included 51 patients (mean age, 46 years) with biopsy-proven breast cancer from May 2015 to April 2018, who were candidates for NAT. Patients underwent both CEM and MRI before, during, and after NAT: pre-NAT, mid-NAT, and post-NAT, respectively. Post-NAT CEM included a 6-minute delayed acquisition. One breast radiologist with experience in CEM reviewed CEM examinations; one radiologist with experience in MRI reviewed MRI examinations.

Compared with pathology, post-NAT CEM, MRI, and delayed CEM systematically overestimated residual tumor size by 0.8 mm, 1.9 mm, and 1.2 mm, respectively. For detecting pathologic complete response by post-NAT imaging, sensitivity and specificity were 81% and 83% for CEM, 100% and 86% for MRI, and 81% and 89% for delayed CEM.

"While MRI remains the preferred test for NAT monitoring," the authors of the AJR article concluded, "the findings support CEM as a useful alternative when MRI is contraindicated or not tolerated."

Explore further

PET/MRI, CT metrics assess pathologic response of pancreas cancer to neoadjuvant therapy

More information: D. Bernardi et al, Contrast-Enhanced Mammography Versus MRI in the Evaluation of Neoadjuvant Therapy Response in Patients With Breast Cancer: A Prospective Study, American Journal of Roentgenology (2022). DOI: 10.2214/AJR.22.27756
Citation: Contrast-enhanced mammography vs. MRI: Neoadjuvant therapy response in breast cancer (2022, June 22) retrieved 7 July 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors